| Geoffrey J Bisignani, MD | |
|
911 Ligonier St Ste 104, Latrobe, PA 15650-1805 | |
| (724) 539-9736 | |
| (724) 539-2836 |
| Full Name | Geoffrey J Bisignani |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 31 Years |
| Location | 911 Ligonier St Ste 104, Latrobe, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346345980 | NPI | - | NPPES |
| 1506099 | Other | GATEWAY | |
| 300759 | Other | PA | UPMC |
| 990026 | Other | PA | HIGHMARK BLUE SHIELD |
| 340016149 | Other | RAILROAD MEDICARE | |
| 1743127 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | MD056863L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Excela Health Latrobe Hospital | Latrobe, PA | Hospital |
| Excela Health Westmoreland Regional Hospital | Greensburg, PA | Hospital |
| Excela Health - Frick Hospital | Mount pleasant, PA | Hospital |
| Indiana Regional Medical Center | Indiana, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| G. U., Inc. | 6800782178 | 3 |
News Archive
The U.S. Food and Drug Administration (FDA) has approved Humalog® 200 units/mL KwikPen® (insulin lispro 200 units/mL; U-200), a pre-filled pen containing a concentrated formulation of Lilly's rapid-acting insulin Humalog® (insulin lispro 100 units/mL) to improve glycemic control in people with type 1 and type 2 diabetes, Eli Lilly and Company announced today. Humalog U-200 KwikPen marks the first FDA approval of a concentrated mealtime insulin analog.
The Los Angeles Times reports that states opting against expanded eligibility - among them, some of the nation's unhealthiest - could fall even further behind as the Affordable Care Act is implemented. News outlets also offer reports from Arizona, Michigan, Wisconsin, Ohio, California, Florida and Virginia.
African Americans are at significantly higher risk of developing colorectal cancer, and being diagnosed with the disease at a later stage, than other ethnic groups. That's the finding of a paper being presented at the annual meeting of the American College of Gastroenterology in San Diego.
Nu Skin Enterprises, Inc. announced today the closing of a partial over-allotment option exercise by the underwriters of 569,000 shares of its Class A common stock at $27.00 per share, pursuant to an option granted to the underwriters in connection with its previously announced underwritten secondary public offering of 4.46 million shares of its Class A common stock at $27.00 per share.
› Verified 1 days ago
| Entity Name | G. U., Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093810608 PECOS PAC ID: 6800782178 Enrollment ID: O20040224000673 |
News Archive
The U.S. Food and Drug Administration (FDA) has approved Humalog® 200 units/mL KwikPen® (insulin lispro 200 units/mL; U-200), a pre-filled pen containing a concentrated formulation of Lilly's rapid-acting insulin Humalog® (insulin lispro 100 units/mL) to improve glycemic control in people with type 1 and type 2 diabetes, Eli Lilly and Company announced today. Humalog U-200 KwikPen marks the first FDA approval of a concentrated mealtime insulin analog.
The Los Angeles Times reports that states opting against expanded eligibility - among them, some of the nation's unhealthiest - could fall even further behind as the Affordable Care Act is implemented. News outlets also offer reports from Arizona, Michigan, Wisconsin, Ohio, California, Florida and Virginia.
African Americans are at significantly higher risk of developing colorectal cancer, and being diagnosed with the disease at a later stage, than other ethnic groups. That's the finding of a paper being presented at the annual meeting of the American College of Gastroenterology in San Diego.
Nu Skin Enterprises, Inc. announced today the closing of a partial over-allotment option exercise by the underwriters of 569,000 shares of its Class A common stock at $27.00 per share, pursuant to an option granted to the underwriters in connection with its previously announced underwritten secondary public offering of 4.46 million shares of its Class A common stock at $27.00 per share.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Geoffrey J Bisignani, MD 911 Ligonier St Ste 104, Latrobe, PA 15650-1805 Ph: (724) 539-9736 | Geoffrey J Bisignani, MD 911 Ligonier St Ste 104, Latrobe, PA 15650-1805 Ph: (724) 539-9736 |
News Archive
The U.S. Food and Drug Administration (FDA) has approved Humalog® 200 units/mL KwikPen® (insulin lispro 200 units/mL; U-200), a pre-filled pen containing a concentrated formulation of Lilly's rapid-acting insulin Humalog® (insulin lispro 100 units/mL) to improve glycemic control in people with type 1 and type 2 diabetes, Eli Lilly and Company announced today. Humalog U-200 KwikPen marks the first FDA approval of a concentrated mealtime insulin analog.
The Los Angeles Times reports that states opting against expanded eligibility - among them, some of the nation's unhealthiest - could fall even further behind as the Affordable Care Act is implemented. News outlets also offer reports from Arizona, Michigan, Wisconsin, Ohio, California, Florida and Virginia.
African Americans are at significantly higher risk of developing colorectal cancer, and being diagnosed with the disease at a later stage, than other ethnic groups. That's the finding of a paper being presented at the annual meeting of the American College of Gastroenterology in San Diego.
Nu Skin Enterprises, Inc. announced today the closing of a partial over-allotment option exercise by the underwriters of 569,000 shares of its Class A common stock at $27.00 per share, pursuant to an option granted to the underwriters in connection with its previously announced underwritten secondary public offering of 4.46 million shares of its Class A common stock at $27.00 per share.
› Verified 1 days ago
Whitney R Snowman, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 600 Ligonier St, Latrobe, PA 15650 Phone: 724-539-9736 Fax: 724-539-2836 | |
Norman P Gebrosky, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 911 Ligonier St Ste 104, Latrobe, PA 15650 Phone: 724-539-9736 Fax: 724-539-2836 | |
Stephanie Marie Rubino, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 911 Ligonier St Ste 104, Latrobe, PA 15650 Phone: 724-539-9736 Fax: 724-539-2836 | |
Vincent M Fiorica, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 911 Ligonier St Ste 104, Latrobe, PA 15650 Phone: 724-539-9736 Fax: 724-539-9736 | |
Lawrence E Freedberg, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 600 Ligonier St, Latrobe, PA 15650 Phone: 724-539-9736 Fax: 724-539-2836 |